Majós C, Cos M, Castañer S, Pons A, Gil M, Fernández-Coello A, Macià M, Bruna J, Aguilera C
From the Departments of Radiology, Institut de Diagnòstic per la Imatge (C.M., M.C., S.C., A.P., C.A.)
Centro de Investigación Red en Bioingeniería, Biomateriales y Nanomedicina (C.M., C.A.), Cerdanyola del Vallès, Spain.
AJNR Am J Neuroradiol. 2016 Dec;37(12):2224-2230. doi: 10.3174/ajnr.A4917. Epub 2016 Sep 8.
Current protocols in patients with glioblastoma include performing an MR examination shortly after surgery and then 2-6 weeks after ending concomitant chemoradiotherapy. The assessment of this first postradiotherapy examination is challenging because the pseudoprogression phenomenon may appear. The aim of this study was to explore if performing an MR examination shortly before radiation therapy (preradiotherapy MR imaging) could improve the radiologic assessment of patients with glioblastoma.
A preradiotherapy MR imaging examination was prospectively performed before the start of radiation therapy in 28 consecutive patients with glioblastoma who had undergone surgical resection. Tumor response to chemoradiotherapy was assessed twice: with the early postoperative MR examination as baseline and with the preradiotherapy MR imaging examination as baseline. In addition, tumor growth in the preradiotherapy MR imaging examination was evaluated, and its correlation with patient survival was assessed with Kaplan-Meier analysis and Cox regression.
Tumor progression after radiation therapy was found in 16 patients, corresponding to pseudoprogression in 7 of them (44%). Four assessments of pseudoprogression switched to partial response or stable disease when preradiotherapy MR imaging was the baseline examination, and the ratio of pseudoprogression was reduced to 25% (3 of 12). Significant differences in survival were found when patients were stratified according to the pattern of tumor growth on preradiotherapy MR imaging (median overall survival "no-growth," 837 days; "focal-growth," 582 days; "global-growth," 344 days; P = .001).
Performing a preradiotherapy MR imaging examination may improve the clinical management of patients with glioblastoma by reducing the ratio of pseudoprogression assessments and providing prognostic information.
目前胶质母细胞瘤患者的诊疗方案包括术后不久及同步放化疗结束后2 - 6周进行磁共振成像(MR)检查。首次放疗后检查的评估具有挑战性,因为可能会出现假性进展现象。本研究的目的是探讨在放疗前不久进行MR检查(放疗前MR成像)是否能改善胶质母细胞瘤患者的影像学评估。
对28例连续接受手术切除的胶质母细胞瘤患者在放疗开始前前瞻性地进行放疗前MR成像检查。对放化疗的肿瘤反应进行两次评估:以术后早期MR检查为基线,以及以放疗前MR成像检查为基线。此外,评估放疗前MR成像检查中的肿瘤生长情况,并通过Kaplan - Meier分析和Cox回归评估其与患者生存的相关性。
16例患者放疗后出现肿瘤进展,其中7例(44%)为假性进展。当以放疗前MR成像为基线检查时,4例假性进展评估转变为部分缓解或病情稳定,假性进展比例降至25%(12例中的3例)。根据放疗前MR成像上的肿瘤生长模式对患者进行分层时,生存存在显著差异(中位总生存期:“无生长”,837天;“局灶性生长”,582天;“整体生长”,344天;P = 0.001)。
进行放疗前MR成像检查可能通过降低假性进展评估比例并提供预后信息来改善胶质母细胞瘤患者的临床管理。